Gujarat Themis Biosyn Ltd · NSE:GUJTHEM
Gujarat Themis Biosyn — Q4 FY2024-25 Earnings Presentation
15 slides from Gujarat Themis Biosyn's earnings presentation, 2025
Slide 1: Gujarat Themis Biosyn Limited Investor Presentation Q4 FY2024-25
Gujarat Themis Biosyn Limited Investor Presentation Q4 FY2024-25
Slide 2: Disclaimer
Click to edit Master title style Disclaimer This presentation has been prepared by Gujarat Themis Biosyn Limited (the “Company” or “GTBL”) solely for information purposes and does not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form t
Slide 3: Management Comment
Click to edit MasterComment Management title style Commenting on the result, Dr. Sachin Patel, Director said: “We have closed the financial year on a fairly decent note, with a strong balance sheet and cash flow. While volatility in inventory impacted overall topline, our production levels remained
Slide 4: Quarterly Financial Highlights
Click to edit Master Quarterly titleHighlights Financial style Revenue (Rs. Cr) 42.0 38.8 39.5 34.7 37.7 Q4 FY23-24 Q1 FY24-25 Q2 FY24-25 Q3 FY24-25 Q4 FY24-25 EBITDA (Rs. Cr) / Margin (%) PAT (Rs. Cr) / Margin (%) 25 52% 49.8% 37.8% 34.1% 50% 18 40% 20 47.8% 47.7% 16 32.8% 31.8% 42.5% 48% 30.4% 35%
Slide 5: Q4 FY24-25 Financial Highlights
Click to Q4edit Master FY24-25 title style Financial Highlights Rs. Crs Q4 FY24-25 Q4 FY23-24 YoY% Q3 FY24-25 Income from Operations 37.74 42.01 39.52 Other Operating Income 0.00 0.00 0.00 Total Income from Operations 37.74 42.01 (10.18%) 39.52 Cost of Materials Consumed 6.85 6.14 6.55 Changes In In
Slide 6: FY24-25 Financial Highlights
Click to edit Master FY24-25 title Financial style Highlights Rs. Crs FY24-25 FY23-24 YoY% Income from Operations 150.80 169.82 Other Operating Income 0.00 0.00 Total Income from Operations 150.80 169.82 (11.20%) Cost of Materials Consumed 25.78 25.67 Changes In Inventory (1.27) 11.01 Employee Cost
Slide 7: Annual Financial Highlights
Click to edit Master Annual Financialtitle style Highlights Revenue (Rs. Cr) 169.82 148.39 150.80 114.85 90.56 FY20-21 FY21-22 FY22-23 FY23-24 FY24-25 EBITDA (Rs. Cr) / Margin (%) PAT (Rs. Cr) / Margin (%) 90 50.5% 49.6% 51% 46.4% 80 50% 70 45% 38.0% 39.1% 45.7% 49% 34.8% 40% 70 60 33.3% 48% 32.3% 6
Slide 8: Balance Sheet Highlights – As on 31st March 2025
Click to edit Master Balance title style– As on 31st March 2025 Sheet Highlights Rs. Cr. As on 31st As on 31st Rs. Cr. As on 31st Mar, As on 31st Mar Total Equity & Liabilities Mar, 2025 Mar 2024 Total Assets 2025 2024 Shareholders Funds 248.38 201.38 Non Current Assets 249.34 173.55 Share Capital 1
Slide 9: Key Balance Sheet Ratios
Keyedit Click to Balance Sheet Master Ratios title style RoCE(%)* RoA(%)** 35.6% 34.9% 57.9% 26.8% 52.1% 39.4% 16.2% 23.6% FY21-22 FY22-23 FY23-24 FY24-25 FY21-22 FY22-23 FY23-24 FY24-25 RoE(%)*** 42.2% 38.9% 29.4% 19.6% FY21-22 FY22-23 FY23-24 FY24-25 Company has been investing in Capex over last t
Slide 10: Fermentation based Intermediate manufacturer
Click Among to edit India’s Masterfew title style Fermentation based Intermediate manufacturer GTBL among one of India’s few fermentation-based manufacturers in pharmaceutical field State of Art Manufacturing Facility Incorporated in 1981 as joint Plant in Vapi (Gujarat) sector Company with GIIC
Slide 11: Product Portfolio – Growing at a fast pace
Click toStrong edit Master & Niche title style Product Portfolio – Growing at a fast pace Current Product Portfolio Rifamycin An intermediate for Rifamycin S An intermediate for manufacturing drug Rifampicin O manufacturing drug Rifaximin (Anti biotic used for treatment of (Antibiotic used for t
Slide 12: Expansion Strategy to Spur Growth
Click to edit Master Expansion titletostyle Strategy Spur Growth Capex Plan Research & Development Forward Integration Fermentation Ventured into API production as New Product Development part of forward integration Expanding fermentation capacity R&D Unit Commissioned, as per strategy Add
Slide 13: State of Art Manufacturing Facilities at Vapi
Click to editofMaster State title style Facilities at Vapi Art Manufacturing Among very few companies in India with fermentation capabilities for Intermediates Environment Friendly & Sustainable Process Using Aerobic Bacteria for Fermentation 13
Slide 14: Our Way Ahead
Click to Ouredit Way Master Aheadtitle style In process of identifying new products which have good domestic & export New Product Development & potential Company strategizing to move up the value chain through forward integration into Forward Integration API – recently began commercial operation
Slide 15: Thank You
Click to editYou Thank Master title style For further information, please contact: Company : Investor Relations Advisors : Gujarat Themis Biosyn Limited Adfactors PR Pvt. Ltd. Mr. Pradeep Chandan Mr. Rahul Trivedi Mr. Savli Mangle pradeep.chandan@themismedicare.com rahul.trivedi@adfactorspr.com savl
Gujarat Themis Biosyn — Q4 FY2024-25 Earnings Presentation on 6ix